{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:47:29Z","timestamp":1795024049659,"version":"4.10.2"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82074221"],"award-info":[{"award-number":["82074221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2023-NHLHCRF-DJMS-04"],"award-info":[{"award-number":["2023-NHLHCRF-DJMS-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-03953-3","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T14:40:52Z","timestamp":1739284852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["New insights in the treatment of DKD: recent advances and future prospects"],"prefix":"10.1186","volume":"26","author":[{"given":"Meimei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"3953_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"3953_CR2","doi-asserted-by":"crossref","unstructured":"Ruiz-Ortega M, Rodrigues-Diez RR, Lavoz C, Rayego-Mateos S. Special Issue Diabetic Nephropathy: diagnosis, Prevention and Treatment. J Clin Med 2020, 9(3).","DOI":"10.3390\/jcm9030813"},{"key":"3953_CR3","doi-asserted-by":"publisher","first-page":"1078371","DOI":"10.3389\/fnut.2023.1078371","volume":"10","author":"W Liu","year":"2023","unstructured":"Liu W, Zhou L, Yin W, Wang J, Zuo X. Global, regional, and national burden of chronic kidney disease attributable to high sodium intake from 1990 to 2019. Front Nutr. 2023;10:1078371.","journal-title":"Front Nutr"},{"key":"3953_CR4","doi-asserted-by":"publisher","first-page":"1379634","DOI":"10.3389\/fendo.2024.1379634","volume":"15","author":"H Wei","year":"2024","unstructured":"Wei H, Ren J, Li R, Qi X, Yang F, Li Q. Global, regional, and national burden of chronic kidney disease attributable to high fasting plasma glucose from 1990 to 2019: a systematic analysis from the global burden of disease study 2019. Front Endocrinol (Lausanne). 2024;15:1379634.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"3953_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000534071","volume":"148","author":"M Ying","year":"2024","unstructured":"Ying M, Shao X, Qin H, Yin P, Lin Y, Wu J, et al. Disease Burden and Epidemiological trends of chronic kidney disease at the Global, Regional, National levels from 1990 to 2019. Nephron. 2024;148(2):113\u201323.","journal-title":"Nephron"},{"issue":"6","key":"3953_CR6","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1172\/JCI72271","volume":"124","author":"K Reidy","year":"2014","unstructured":"Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124(6):2333\u201340.","journal-title":"J Clin Invest"},{"issue":"2 Suppl 2","key":"3953_CR7","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1053\/j.ajkd.2013.10.047","volume":"63","author":"SS Badal","year":"2014","unstructured":"Badal SS, Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis. 2014;63(2 Suppl 2):S63\u201383.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"3953_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.mcna.2023.03.004","volume":"107","author":"S Gupta","year":"2023","unstructured":"Gupta S, Dominguez M, Golestaneh L. Diabetic kidney disease: an update. Med Clin North Am. 2023;107(4):689\u2013705.","journal-title":"Med Clin North Am"},{"issue":"12","key":"3953_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-8587(18)30289-4","volume":"6","author":"D de Zeeuw","year":"2018","unstructured":"de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018;6(12):925\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3953_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","volume":"102","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102(2):248\u201360.","journal-title":"Kidney Int"},{"key":"3953_CR11","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.","journal-title":"Nat Rev Dis Primers"},{"issue":"46","key":"3953_CR12","doi-asserted-by":"publisher","first-page":"29013","DOI":"10.1073\/pnas.2005905117","volume":"117","author":"X Sheng","year":"2020","unstructured":"Sheng X, Qiu C, Liu H, Gluck C, Hsu JY, He J, et al. Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. Proc Natl Acad Sci U S A. 2020;117(46):29013\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3953_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.2337\/db17-0914","volume":"67","author":"NR van Zuydam","year":"2018","unstructured":"van Zuydam NR, Ahlqvist E, Sandholm N, Deshmukh H, Rayner NW, Abdalla M, et al. A Genome-Wide Association Study of Diabetic Kidney Disease in subjects with type 2 diabetes. Diabetes. 2018;67(7):1414\u201327.","journal-title":"Diabetes"},{"issue":"10","key":"3953_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1681\/ASN.2019030218","volume":"30","author":"RM Salem","year":"2019","unstructured":"Salem RM, Todd JN, Sandholm N, Cole JB, Chen WM, Andrews D, et al. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. J Am Soc Nephrol. 2019;30(10):2000\u201316.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3953_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40246-019-0205-7","volume":"13","author":"M Guan","year":"2019","unstructured":"Guan M, Keaton JM, Dimitrov L, Hicks PJ, Xu J, Palmer ND, et al. Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African americans. Hum Genomics. 2019;13(1):21.","journal-title":"Hum Genomics"},{"issue":"9","key":"3953_CR16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.4239\/wjd.v15.i9.1874","volume":"15","author":"M Jeyaraman","year":"2024","unstructured":"Jeyaraman M, Mariappan T, Jeyaraman N, Muthu S, Ramasubramanian S, Santos GS, et al. Gut microbiome: a revolution in type II diabetes mellitus. World J Diabetes. 2024;15(9):1874\u201388.","journal-title":"World J Diabetes"},{"issue":"1","key":"3953_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12937-024-00939-z","volume":"23","author":"CF Lu","year":"2024","unstructured":"Lu CF, Cang XM, Liu WS, Wang LH, Huang HY, Wang XQ, et al. A late eating midpoint is associated with increased risk of diabetic kidney disease: a cross-sectional study based on NHANES 2013\u20132020. Nutr J. 2024;23(1):39.","journal-title":"Nutr J"},{"issue":"12","key":"3953_CR18","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.7150\/thno.84650","volume":"13","author":"PP Chen","year":"2023","unstructured":"Chen PP, Zhang JX, Li XQ, Li L, Wu QY, Liu L, et al. Outer membrane vesicles derived from gut microbiota mediate tubulointerstitial inflammation: a potential new mechanism for diabetic kidney disease. Theranostics. 2023;13(12):3988\u20134003.","journal-title":"Theranostics"},{"issue":"2","key":"3953_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1017\/S0954422420000104","volume":"33","author":"ME Garay-Sevilla","year":"2020","unstructured":"Garay-Sevilla ME, Beeri MS, de la Maza MP, Rojas A, Salazar-Villanea S, Uribarri J. The potential role of dietary advanced glycation endproducts in the development of chronic non-infectious diseases: a narrative review. Nutr Res Rev. 2020;33(2):298\u2013311.","journal-title":"Nutr Res Rev"},{"key":"3953_CR20","doi-asserted-by":"publisher","first-page":"108645","DOI":"10.1016\/j.diabres.2020.108645","volume":"172","author":"S Zhang","year":"2021","unstructured":"Zhang S, Cai Y, Meng C, Ding X, Huang J, Luo X, et al. The role of the microbiome in diabetes mellitus. Diabetes Res Clin Pract. 2021;172:108645.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"3953_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1681\/ASN.2013080905","volume":"25","author":"A Ramezani","year":"2014","unstructured":"Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657\u201370.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"3953_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","volume":"117","author":"YC Lin","year":"2018","unstructured":"Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018;117(8):662\u201375.","journal-title":"J Formos Med Assoc"},{"key":"3953_CR23","doi-asserted-by":"publisher","first-page":"155195","DOI":"10.1016\/j.metabol.2022.155195","volume":"131","author":"L Yao","year":"2022","unstructured":"Yao L, Liang X, Qiao Y, Chen B, Wang P, Liu Z. Mitochondrial dysfunction in diabetic tubulopathy. Metabolism. 2022;131:155195.","journal-title":"Metabolism"},{"issue":"5","key":"3953_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrneph.2018.9","volume":"14","author":"JM Forbes","year":"2018","unstructured":"Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291\u2013312.","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"3953_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","volume":"20","author":"DH van Raalte","year":"2024","unstructured":"van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, Gordin D, et al. Combination therapy for kidney disease in people with diabetes mellitus. Nat Rev Nephrol. 2024;20(7):433\u201346.","journal-title":"Nat Rev Nephrol"},{"issue":"24","key":"3953_CR26","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1161\/CIRCULATIONAHA.122.061033","volume":"146","author":"RA Scholtes","year":"2022","unstructured":"Scholtes RA, Hesp AC, Mosterd CM, Geurts F, Hoorn EJ, Touw DJ, et al. Kidney hemodynamic effects of Angiotensin receptor blockade, sodium-glucose Cotransporter-2 inhibition alone, and their combination: a crossover randomized trial in people with type 2 diabetes. Circulation. 2022;146(24):1895\u20137.","journal-title":"Circulation"},{"issue":"12","key":"3953_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"3953_CR28","first-page":"341","volume":"101","author":"DK Smith","year":"2020","unstructured":"Smith DK, Lennon RP, Carlsgaard PB. Managing hypertension using combination therapy. Am Fam Physician. 2020;101(6):341\u20139.","journal-title":"Am Fam Physician"},{"issue":"6","key":"3953_CR29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273\u201392.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"3953_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4093\/dmj.2020.0217","volume":"45","author":"T Yamazaki","year":"2021","unstructured":"Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of Diabetic kidney disease: current and future. Diabetes Metab J. 2021;45(1):11\u201326.","journal-title":"Diabetes Metab J"},{"key":"3953_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and Cardiovascular function. Annu Rev Physiol. 2021;83:503\u201328.","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"3953_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-020-01163-9","volume":"19","author":"F Giorgino","year":"2020","unstructured":"Giorgino F, Vora J, Fenici P, Solini A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc Diabetol. 2020;19(1):196.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3953_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","volume":"21","author":"AD Kaze","year":"2022","unstructured":"Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022;21(1):47.","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"3953_CR34","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"11","key":"3953_CR35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"3953_CR36","doi-asserted-by":"publisher","first-page":"F1017","DOI":"10.1152\/ajprenal.00021.2020","volume":"318","author":"J Hodrea","year":"2020","unstructured":"Hodrea J, Balogh DB, Hosszu A, Lenart L, Besztercei B, Koszegi S, et al. Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney. Am J Physiol Ren Physiol. 2020;318(4):F1017\u201329.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"5S","key":"3953_CR37","first-page":"S1","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work G","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127.","journal-title":"Kidney Int"},{"issue":"12","key":"3953_CR38","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a Consensus Report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"issue":"11","key":"3953_CR39","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ekir.2022.08.016","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(11):2546\u20137.","journal-title":"Kidney Int Rep"},{"key":"3953_CR40","doi-asserted-by":"crossref","unstructured":"Yaribeygi H, Atkin SL, Montecucco F, Jamialahmadi T, Sahebkar A. Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus. Biomed Res Int. 2021, 2021: 8163153.","DOI":"10.1155\/2021\/8163153"},{"key":"3953_CR41","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.","journal-title":"Mol Metab"},{"issue":"19","key":"3953_CR42","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"9","key":"3953_CR43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839\u201348.","journal-title":"N Engl J Med"},{"issue":"10193","key":"3953_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131\u20138.","journal-title":"Lancet"},{"key":"3953_CR45","doi-asserted-by":"crossref","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G et al. Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024.","DOI":"10.1056\/NEJMoa2403347"},{"key":"3953_CR46","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3953_CR47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","volume":"84","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal diseases. Annu Rev Physiol. 2022;84:585\u2013610.","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"3953_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","volume":"10","author":"JW Funder","year":"2005","unstructured":"Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10(1):15\u201322.","journal-title":"Heart Fail Rev"},{"issue":"2","key":"3953_CR49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.freeradbiomed.2012.05.011","volume":"53","author":"N Queisser","year":"2012","unstructured":"Queisser N, Schupp N. Aldosterone, oxidative stress, and NF-kappaB activation in hypertension-related cardiovascular and renal diseases. Free Radic Biol Med. 2012;53(2):314\u201327.","journal-title":"Free Radic Biol Med"},{"issue":"15","key":"3953_CR50","first-page":"1787","volume":"81","author":"JE Frampton","year":"2021","unstructured":"Frampton JE, Finerenone. First Approval Drugs. 2021;81(15):1787\u201394.","journal-title":"First Approval Drugs"},{"issue":"10","key":"3953_CR51","doi-asserted-by":"publisher","first-page":"102638","DOI":"10.1016\/j.dsx.2022.102638","volume":"16","author":"AK Singh","year":"2022","unstructured":"Singh AK, Singh A, Singh R, Misra A. Finerenone in diabetic kidney disease: a systematic review and critical appraisal. Diabetes Metab Syndr. 2022;16(10):102638.","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"3953_CR52","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"23","key":"3953_CR53","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on chronic kidney Disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"9\u201310","key":"3953_CR54","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000532102","volume":"54","author":"D Koya","year":"2023","unstructured":"Koya D, Anker SD, Ruilope LM, Rossing P, Liu Z, Lee BW, et al. Cardiorenal Outcomes with Finerenone in Asian patients with chronic kidney disease and type 2 diabetes: a FIDELIO-DKD post hoc analysis. Am J Nephrol. 2023;54(9\u201310):370\u20138.","journal-title":"Am J Nephrol"},{"key":"3953_CR55","doi-asserted-by":"publisher","first-page":"1125693","DOI":"10.3389\/fendo.2023.1125693","volume":"14","author":"R Lv","year":"2023","unstructured":"Lv R, Xu L, Che L, Liu S, Wang Y, Dong B. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front Endocrinol (Lausanne). 2023;14:1125693.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"39","key":"3953_CR56","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"1","key":"3953_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia Risk with Finerenone: results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3953_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.13018","volume":"20","author":"ES Andersen","year":"2018","unstructured":"Andersen ES, Deacon CF, Holst JJ. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes Metab. 2018;20(1):34\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"3953_CR59","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.phrs.2017.12.001","volume":"129","author":"G Coppolino","year":"2018","unstructured":"Coppolino G, Leporini C, Rivoli L, Ursini F, di Paola ED, Cernaro V, et al. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacol Res. 2018;129:274\u201394.","journal-title":"Pharmacol Res"},{"key":"3953_CR60","doi-asserted-by":"publisher","first-page":"105019","DOI":"10.1016\/j.phrs.2020.105019","volume":"159","author":"R Nicotera","year":"2020","unstructured":"Nicotera R, Casarella A, Longhitano E, Bolignano D, Andreucci M, De Sarro G, et al. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. Pharmacol Res. 2020;159:105019.","journal-title":"Pharmacol Res"},{"issue":"1","key":"3953_CR61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular events in adults with type 2 diabetes and High Cardiovascular and renal risk: the CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"6","key":"3953_CR62","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"C Pollock","year":"2019","unstructured":"Pollock C, Stefansson B, Reyner D, Rossing P, Sjostrom CD, Wheeler DC, et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(6):429\u201341.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3953_CR63","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.ajkd.2015.03.024","volume":"66","author":"ME Cooper","year":"2015","unstructured":"Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, et al. Kidney disease end points in a pooled analysis of individual patient-Level Data from a large clinical trials program of the Dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. 2015;66(3):441\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3953_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.kint.2022.10.030","volume":"103","author":"S Rayego-Mateos","year":"2023","unstructured":"Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernandez C, Marchant V, Donate-Correa J, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2023;103(2):282\u201396.","journal-title":"Kidney Int"},{"key":"3953_CR65","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2021.05.025","volume":"171","author":"XQ Wu","year":"2021","unstructured":"Wu XQ, Zhang DD, Wang YN, Tan YQ, Yu XY, Zhao YY. AGE\/RAGE in diabetic kidney disease and ageing kidney. Free Radic Biol Med. 2021;171:260\u201371.","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"3953_CR66","doi-asserted-by":"publisher","first-page":"e14823","DOI":"10.1016\/j.heliyon.2023.e14823","volume":"9","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ma XZ, Zhao XY, Li JJ, Ma S, Pang ZD, et al. AGEs-RAGE-K(ca)3.1 pathway mediates palmitic acid-induced migration of PBMCs from patients with type 2 diabetes. Heliyon. 2023;9(4):e14823.","journal-title":"Heliyon"},{"key":"3953_CR67","doi-asserted-by":"crossref","unstructured":"Khalid M, Petroianu G, Adem A. Advanced Glycation End products and Diabetes Mellitus: mechanisms and perspectives. Biomolecules 2022, 12(4).","DOI":"10.3390\/biom12040542"},{"issue":"11","key":"3953_CR68","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","volume":"33","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, et al. JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial. Nephrol Dial Transpl. 2018;33(11):1950\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"3953_CR69","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.pharmthera.2005.08.012","volume":"110","author":"S Motte","year":"2006","unstructured":"Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110(3):386\u2013414.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"3953_CR70","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2215\/CJN.13601021","volume":"16","author":"A Ortiz","year":"2021","unstructured":"Ortiz A, Fernandez-Fernandez B, Atrasentan. The difficult Task of integrating endothelin A receptor antagonists into current treatment paradigm for Diabetic kidney disease. Clin J Am Soc Nephrol. 2021;16(12):1775\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3953_CR71","doi-asserted-by":"publisher","first-page":"174503","DOI":"10.1016\/j.ejphar.2021.174503","volume":"911","author":"X Bai","year":"2021","unstructured":"Bai X, Nie P, Lou Y, Zhu Y, Jiang S, Li B, et al. Pirfenidone is a renal protective drug: mechanisms, signalling pathways, and preclinical evidence. Eur J Pharmacol. 2021;911:174503.","journal-title":"Eur J Pharmacol"},{"key":"3953_CR72","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fcell.2020.00123","volume":"8","author":"YY Gu","year":"2020","unstructured":"Gu YY, Liu XS, Huang XR, Yu XQ, Lan HY. Diverse role of TGF-beta in kidney disease. Front Cell Dev Biol. 2020;8:123.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"3953_CR73","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2215\/CJN.01050207","volume":"2","author":"ME Cho","year":"2007","unstructured":"Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2(5):906\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3953_CR74","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1681\/ASN.2010101049","volume":"22","author":"K Sharma","year":"2011","unstructured":"Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22(6):1144\u201351.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3953_CR75","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/j.ajkd.2021.11.010","volume":"80","author":"M Ruiz-Ortega","year":"2022","unstructured":"Ruiz-Ortega M, Lamas S, Ortiz A. Antifibrotic agents for the management of CKD: a review. Am J Kidney Dis. 2022;80(2):251\u201363.","journal-title":"Am J Kidney Dis"},{"key":"3953_CR76","doi-asserted-by":"publisher","first-page":"108895","DOI":"10.1016\/j.biopha.2019.108895","volume":"115","author":"S Wang","year":"2019","unstructured":"Wang S, Zhou Y, Zhang Y, He X, Zhao X, Zhao H, et al. Roscovitine attenuates renal interstitial fibrosis in diabetic mice through the TGF-beta1\/p38 MAPK pathway. Biomed Pharmacother. 2019;115:108895.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"3953_CR77","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1681\/ASN.2018121231","volume":"30","author":"GM Chertow","year":"2019","unstructured":"Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD, et al. Effects of Selonsertib in patients with Diabetic kidney disease. J Am Soc Nephrol. 2019;30(10):1980\u201390.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"3953_CR78","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41581-022-00608-6","volume":"18","author":"N Mahtal","year":"2022","unstructured":"Mahtal N, Lenoir O, Tinel C, Anglicheau D, Tharaux PL. MicroRNAs in kidney injury and disease. Nat Rev Nephrol. 2022;18(10):643\u201362.","journal-title":"Nat Rev Nephrol"},{"key":"3953_CR79","doi-asserted-by":"publisher","first-page":"1238981","DOI":"10.3389\/fendo.2023.1238981","volume":"14","author":"Q Wu","year":"2023","unstructured":"Wu Q, Huang F. LncRNA H19: a novel player in the regulation of diabetic kidney disease. Front Endocrinol (Lausanne). 2023;14:1238981.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3953_CR80","doi-asserted-by":"publisher","first-page":"101851","DOI":"10.1016\/j.redox.2020.101851","volume":"40","author":"V Miguel","year":"2021","unstructured":"Miguel V, Ramos R, Garcia-Bermejo L, Rodriguez-Puyol D, Lamas S. The program of renal fibrogenesis is controlled by microRNAs regulating oxidative metabolism. Redox Biol. 2021;40:101851.","journal-title":"Redox Biol"},{"key":"3953_CR81","doi-asserted-by":"crossref","unstructured":"Gale DP, Gross O, Wang F, de la Esteban RJ, Hall M, Sayer JA et al. A Randomized Controlled Clinical Trial Testing effects of Lademirsen on kidney function decline in adults with Alport Syndrome. Clin J Am Soc Nephrol 2024.","DOI":"10.2215\/CJN.0000000000000458"},{"key":"3953_CR82","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","volume":"10","author":"ARR Weiss","year":"2019","unstructured":"Weiss ARR, Dahlke MH. Immunomodulation by Mesenchymal Stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol. 2019;10:1191.","journal-title":"Front Immunol"},{"issue":"3","key":"3953_CR83","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3109\/21691401.2015.1129620","volume":"44","author":"S Kariminekoo","year":"2016","unstructured":"Kariminekoo S, Movassaghpour A, Rahimzadeh A, Talebi M, Shamsasenjan K, Akbarzadeh A. Implications of mesenchymal stem cells in regenerative medicine. Artif Cells Nanomed Biotechnol. 2016;44(3):749\u201357.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3953_CR84","doi-asserted-by":"crossref","unstructured":"Bochon B, Kozubska M, Surygala G, Witkowska A, Kuzniewicz R, Grzeszczak W et al. Mesenchymal stem cells-potential applications in kidney diseases. Int J Mol Sci 2019, 20(10).","DOI":"10.3390\/ijms20102462"},{"issue":"3","key":"3953_CR85","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","volume":"4","author":"JM Karp","year":"2009","unstructured":"Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206\u201316.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"3953_CR86","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40478-022-01316-9","volume":"10","author":"SL Lindsay","year":"2022","unstructured":"Lindsay SL, Moleda AM, MacLellan LM, Keh SM, McElroy DE, Linington C, et al. Human olfactory mesenchymal stromal cell transplantation ameliorates experimental autoimmune encephalomyelitis revealing an inhibitory role for IL16 on myelination. Acta Neuropathol Commun. 2022;10(1):12.","journal-title":"Acta Neuropathol Commun"},{"key":"3953_CR87","doi-asserted-by":"crossref","unstructured":"Guo Q, Li P, Chen M, Yu Y, Wan Y, Zhang Z et al., Exosomes From Human Umbilical Cord Stem Cells Suppress Macrophage-to-myofibroblast Transition, Alleviating Renal Fibrosis. Inflammation. 2024.","DOI":"10.1007\/s10753-024-02027-0"},{"issue":"1","key":"3953_CR88","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s13287-021-02429-z","volume":"12","author":"H Tang","year":"2021","unstructured":"Tang H, Zhang P, Zeng L, Zhao Y, Xie L, Chen B. Mesenchymal stem cells ameliorate renal fibrosis by galectin-3\/Akt\/GSK3beta\/Snail signaling pathway in adenine-induced nephropathy rat. Stem Cell Res Ther. 2021;12(1):409.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"3953_CR89","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13287-022-02927-8","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Chen J, Liang H, Cai Y, Li X, Yan L, et al. Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK\/ERK signaling. Stem Cell Res Ther. 2022;13(1):258.","journal-title":"Stem Cell Res Ther"},{"key":"3953_CR90","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","volume":"12","author":"DK Packham","year":"2016","unstructured":"Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in Diabetic Nephropathy: a Randomized, Placebo-controlled, dose escalation study. EBioMedicine. 2016;12:263\u20139.","journal-title":"EBioMedicine"},{"issue":"6","key":"3953_CR91","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated Lifetime Cardiovascular, kidney, and Mortality benefits of Combination Treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with Conventional Care in patients with type 2 diabetes and Albuminuria. Circulation. 2024;149(6):450\u201362.","journal-title":"Circulation"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03953-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-03953-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03953-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T02:00:14Z","timestamp":1739325614000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-03953-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3953"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-03953-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"72"}}